Axumin-enhanced PET scans becoming more widely available

Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …

Comparison of gallium-68- and choline-C11-based PET/CT scanning in high-risk and progressive prostate cancers

The question of how much better the varied, new forms of imaging will be in the evaluation of patients with higher-risk prostate cancer both before and after their treatment is a currently “hot topic” in the world of prostate cancer. … READ MORE …

Will restriction spectrum imaging replace multiparametric MRI?

Researchers at the University of California San Diego have developed a new kind of MRI called restriction spectrum imaging MRI or just RSI-MRI that seems to discriminate among Gleason grades 3, 4, and 5 with unmatched geographic precision. … READ MORE …

New fluorine-18-based imaging agent approved in USA

Last Friday the US Food and Drug Administration (FDA) last Friday approved a new type of imaging agent for use in PET/CT scans for men with suspected prostate cancer recurrence after earlier treatment. … READ MORE …

What’s happening at the annual EAU meeting in Munich?

So our friends at UroToday have started providing reports on the key presentations that are being given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. Here are links to some interesting reports … READ MORE …

CureTalk program on imaging and genomics with Dr. David Lee

Yesterday evening we held a CureTalk program on the roles of new imaging and genomic/genetic tests in the diagnosis, work-up, and prognosis of prostate cancer with Dr. David Lee of the University of Pennsylvania. … READ MORE …

Upcoming prostate cancer CureTalk on February 9

The next, scheduled prostate cancer CureTalk will be at 6:00 p.m. Eastern time on February 9, 2016, and will address the use of newer imaging and genomic testing methods in the diagnosis and management of prostate cancer. … READ MORE …

Targeting treatments for extraprostatic and oligometastatic prostate cancer with curative intent

The moderator of a well-known, prostate cancer-specific Internet forum recently wrote to us, stating,

There has been some assumption on the part of users of internet patient forums that the [newer and] more sensitive scans can be useful to detect major tumors that can be removed laparoscopically or treated with radiation, and that this would be beneficial.

… READ MORE …

Newer types of whole body scanning are likely to be significantly better than older bone scans, but …

A new report in the Journal of Nuclear Medicine has suggested that it may be time to start looking seriously at whether the combined [18F]NaF/[18F]FDG PET/CT scan may be significantly better than the traditional [99m]Tc bone scan in evaluation of risk for or the actual presence of metastasis in men with prostate cancer. … READ MORE …

The evolution of nuclear imaging in the management of prostate cancer

What is properly known as “nuclear imaging” is the use of (usually injectable) radioactive compounds into the body that have no known clinical effects but which can be targeted to “light up” and demonstrate the presence of specific types of tissue. … READ MORE …

> 40 percent of low-risk prostate cancer patients were getting inappropriate imaging tests

A new paper in JAMA Oncology has shown that between 2004 and 2007 nearly 45 percent of men initially diagnosed with low-risk prostate cancer were receiving unnecessary bone scans and CT scans in some regions of the USA. … READ MORE …

RSI-MRI — a new entrant into the prostate cancer imaging field

According to an article published recently in Prostate Cancer and Prostatic Diseases, a “better” form of MRI may be able to improve the accuracy of prostate imaging over current techniques. … READ MORE …

Next prostate cancer CureTalk on January 20

The next CureTalk program on prostate cancer is scheduled for January 20, 2015, at 5:00 p.m. Eastern time in the USA. The featured speaker is Dr. James Mohler of the Roswell Park Cancer Center in Buffalo, New York. To register for this program, … READ MORE …

Potential new imaging agent in diagnosis, monitoring of prostate cancer

About 19 months ago we reported that a company called Progenics Pharmaceuticals had acquired all rights to a small, radiolabeled molecule known as [99mTc]MIP-1404, and that an international, multi-center Phase II trial was  investigating the clinical activity of [99mTc]MIP-1404 as a prostate cancer imaging agent. … READ MORE …

7-T MRIs in the diagnosis and work-up of localized prostate cancer

References to 1.5-T, 3-T, and 7-T MRI machines are based on the size and power of the magnets used in the creation of MRI images by the machines. The T stands for “tesla”. It is a measure of magnetic flux density, and one tesla (1 T) is equal to one weber per square metre (1 Wb/m2). … READ MORE …